Title: In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20181001
Title: Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats.
Journal: Toxicology and applied pharmacology 20170701
Title: Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Journal: Journal of neuroimmunology 20121015
Title: Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.
Journal: Journal of neuroimmunology 20121015
Title: Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Journal: Acta neuropathologica 20120901
Title: Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.
Journal: The American journal of pathology 20120801
Title: Oral laquinimod for multiple sclerosis.
Journal: The New England journal of medicine 20120628
Title: Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Journal: Revista de neurologia 20120616
Title: Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.
Journal: Bone marrow transplantation 20120601
Title: Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Journal: Expert review of clinical pharmacology 20120501
Title: Drugs: An injection of hope.
Journal: Nature 20120412
Title: Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Journal: The New England journal of medicine 20120315
Title: New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
Journal: Current opinion in neurology 20120201
Title: Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
Journal: Clinical immunology (Orlando, Fla.) 20120101
Title: Laquinimod in multiple sclerosis.
Journal: Clinical immunology (Orlando, Fla.) 20120101
Title: Current concepts of hyperinflammation in chronic granulomatous disease.
Journal: Clinical & developmental immunology 20120101
Title: Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Journal: The American journal of pathology 20120101
Title: Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.
Journal: Clinical & developmental immunology 20120101
Title: Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.
Journal: PloS one 20120101
Title: Immune therapy of multiple sclerosis--future strategies.
Journal: Current pharmaceutical design 20120101
Title: Current therapeutic options in pediatric multiple sclerosis.
Journal: Current treatment options in neurology 20111201
Title: Emerging oral drugs for relapsing-remitting multiple sclerosis.
Journal: Expert opinion on emerging drugs 20111201
Title: Oral treatment for multiple sclerosis.
Journal: The Lancet. Neurology 20111101
Title: Multiple sclerosis: pathogenesis and treatment.
Journal: Current neuropharmacology 20110901
Title: Insight into the mechanism of laquinimod action.
Journal: Journal of the neurological sciences 20110715
Title: Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.
Journal: Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110401
Title: Oral laquinimod treatment in multiple sclerosis.
Journal: Neurologia (Barcelona, Spain) 20110301
Title: Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Journal: Expert opinion on drug metabolism & toxicology 20110301
Title: [Current treatment of multiple sclerosis].
Journal: Lege artis medicinae : uj magyar orvosi hirmondo 20110201
Title: Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Journal: CNS drugs 20110101
Title: Therapeutic approach to multiple sclerosis by novel oral drug.
Journal: Recent patents on inflammation & allergy drug discovery 20110101
Title: Multiple sclerosis therapeutic pipeline: opportunities and challenges.
Journal: The Mount Sinai journal of medicine, New York 20110101
Title: Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.
Journal: Patient preference and adherence 20110101
Title: Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.
Journal: Core evidence 20110101
Title: Development of oral immunomodulatory agents in the management of multiple sclerosis.
Journal: Drug design, development and therapy 20110101
Title: The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.
Journal: Parkinson's disease 20110101
Title: The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials.
Journal: PloS one 20110101
Title: Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
Journal: ASN neuro 20110101
Title: Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.
Journal: BMC neurology 20110101
Title: Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England) 20101101
Title: Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Journal: Journal of neuroimmunology 20101008
Title: Current and future role of interferon beta in the therapy of multiple sclerosis.
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20101001
Title: Emerging therapies in relapsing-remitting multiple sclerosis.
Journal: Reviews on recent clinical trials 20100901
Title: Treatment options for multiple sclerosis: current and emerging therapies.
Journal: Pharmacotherapy 20100901
Title: Emerging oral agents for multiple sclerosis.
Journal: The American journal of managed care 20100901
Title: Will the newer oral MS agents be welcomed by managed care organizations?
Journal: The American journal of managed care 20100901
Title: New drug therapies for multiple sclerosis.
Journal: Current opinion in neurology 20100601
Title: Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100501
Title: Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Journal: Journal of neuroimmunology 20100415
Title: Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments.
Journal: Journal of pharmacy practice 20100401
Title: Emerging multiple sclerosis oral therapies.
Journal: Neurology 20100105
Title: A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.
Journal: PloS one 20100101
Title: Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.
Journal: Patient preference and adherence 20100101
Title: Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Journal: Therapeutics and clinical risk management 20100101
Title: Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Journal: Drug design, development and therapy 20100101
Title: Multiple sclerosis therapies: molecular mechanisms and future.
Journal: Results and problems in cell differentiation 20100101
Title: Disease-modifying therapies in relapsing-remitting multiple sclerosis.
Journal: Neuropsychiatric disease and treatment 20100101
Title: Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.
Journal: Therapeutics and clinical risk management 20100101
Title: New approaches in the management of multiple sclerosis.
Journal: Drug design, development and therapy 20100101
Title: Emerging therapies for treatment of multiple sclerosis.
Journal: Journal of inflammation research 20100101
Title: The future of multiple sclerosis therapy.
Journal: Pharmacological research 20091001
Title: New oral drugs for multiple sclerosis.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001
Title: Oral laquinimod therapy in relapsing multiple sclerosis.
Journal: Expert opinion on investigational drugs 20090701
Title: Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.
Journal: PLoS biology 20090401
Title: Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
Journal: Central nervous system agents in medicinal chemistry 20090301
Title: Review of teriflunomide and its potential in the treatment of multiple sclerosis.
Journal: Neuropsychiatric disease and treatment 20090101
Title: Recent developments in multiple sclerosis therapeutics.
Journal: BMC medicine 20090101
Title: Promising treatments of tomorrow for multiple sclerosis.
Journal: Annals of Indian Academy of Neurology 20090101
Title: New oral disease-modifying therapies for multiple sclerosis.
Journal: F1000 medicine reports 20090101
Title: Kynurenine pathway metabolites in humans: disease and healthy States.
Journal: International journal of tryptophan research : IJTR 20090101
Title: Identification and development of new therapeutics for multiple sclerosis.
Journal: Trends in pharmacological sciences 20081101
Title: Emerging oral drugs for multiple sclerosis.
Journal: Expert opinion on emerging drugs 20080901
Title: Oral laquinimod for treatment of relapsing-remitting multiple sclerosis.
Journal: The Lancet. Neurology 20080801
Title: Laquinimod, a new oral drug for multiple sclerosis.
Journal: Lancet (London, England) 20080621
Title: Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Journal: Lancet (London, England) 20080621
Title: Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model.
Journal: International journal of biological sciences 20080101
Title: Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
Journal: Drugs 20080101
Title: Novel oral agents for multiple sclerosis.
Journal: Current neurology and neuroscience reports 20070501
Title: Oral disease-modifying treatments for multiple sclerosis: the story so far.
Journal: CNS drugs 20070101
Title: Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
Journal: Journal of neuroimmunology 20060401
Title: Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation.
Journal: The Journal of organic chemistry 20060217
Title: Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling.
Journal: Rapid communications in mass spectrometry : RCM 20060101
Title: Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20050601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20050601
Title: Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Journal: Neurology 20050322
Title: [Future possibilities of the multiple sclerosis treatment].
Journal: Casopis lekaru ceskych 20050101
Title: Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Journal: Journal of neuroimmunology 20041101
Title: Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Journal: Journal of medicinal chemistry 20040408
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040101
Title: Determination of laquinimod in plasma by coupled-column liquid chromatography with ultraviolet absorbance detection.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030305
Title: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Journal: Journal of neuroimmunology 20020901
Title: Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue.
Journal: Neuropharmacology 20020401
Title: Schulze-Topphoff, Ulf., et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012), 7(3), e33797.
Title: Toubi E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol. 2012 Oct 15;251(1-2):45-54.
Title: Brück W, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
Title: Jan Thöne, et al. Laquinimod in the treatment of multiple sclerosis: a review of the data so far. Drug Des Devel Ther. 2016 Mar 14;10:1111-8.
